AXS-07, a cutting-edge oral solution, blends MoSEIC meloxicam and rizatriptan, offering rapid absorption. It ingeniously inhibits CGRP release, counteracting vasodilation, and curbing neuroinflammation and pain transmission for enhanced relief.
AXS-07 demonstrates superior efficacy in swiftly alleviating migraine symptoms with remarkable tolerability, significantly reducing pain and most bothersome symptoms compared to placebo.
At the American Academy of Neurology conference 2024, Axsome Therapeutics unveiled a compelling poster elucidating the combined efficacy and safety of AXS-07 (MOSEICTM Meloxicam and Rizatriptan) through a thorough synthesis of two pivot...